Vivos Therapeutics Revenue Jumps 70% on Sleep Center Acquisition
Event summary
- Vivos Therapeutics reported a 70% year-over-year revenue increase to $5.1 million in Q1 2026, driven by its June 2025 acquisition of The Sleep Center of Nevada (SCN).
- Gross profit rose 103% to $3.1 million, with gross margin improving from 50% to 60%.
- Net loss widened to $7.8 million due to higher operating expenses related to business expansion.
- Oral appliance sales increased 42% to 5,304 units, though revenue from legacy VIP dentist customers declined to $1.4 million.
- Cash and cash equivalents stood at $2.1 million as of March 31, 2026, with stockholders’ equity at a deficit of $1.1 million.
The big picture
Vivos Therapeutics' strategic pivot towards a service-based model, driven by the SCN acquisition, is accelerating revenue growth but also increasing operating costs. The company's focus on reducing customer acquisition costs and improving insurance reimbursement reflects broader industry trends towards value-based healthcare services. The challenge lies in balancing expansion with financial discipline to achieve cash flow positivity.
What we're watching
- Integration Success
- Whether Vivos can fully integrate SCN and other medical provider collaborations to sustain revenue growth.
- Cost Management
- The pace at which Vivos reduces operating expenses and improves cash flow positivity.
- Funding Strategy
- How Vivos secures additional funding to restructure debt and meet operating needs.
Related topics